MCM
SUPN icon

McMillion Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

McMillion Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-300
Closed -$5K – 237
2020
Q1 		$5K Hold
300
– – ﹤0.01% 237
2019
Q4 		$7K Hold
300
– – ﹤0.01% 221
2019
Q3 		$8K Hold
300
– – ﹤0.01% 208
2019
Q2 		$10K Buy
+300
New +$10.3K 0.01% 196

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

McMillion Capital Management's SUPN Position: Q2 2020 in Review

McMillion Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 300 shares — an estimated $5K sold.

McMillion Capital Management first reported a position in SUPN in Q2 2019 and held it in 4 quarters. The position peaked at $10K in Q2 2019. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

  • McMillion Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • McMillion Capital Management sold 300 Supernus Pharmaceuticals shares in Q2 2020, an estimated $5K.
  • McMillion Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • McMillion Capital Management's Supernus Pharmaceuticals position peaked at $10K in Q2 2019.
  • 218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on McMillion Capital Management's 13F filing for Q2 2020, filed 6 Aug 2020.